Description of characteristics, management of care and healthcare direct costs of patients with HR+/HER2- early breast cancer in Italy: a real-world study involving administrative and pathological anatomy databases

References

• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• I numeri del cancro in Italia 2021 [Internet]. AIOM. [cited 2022 Feb 2]. Available from: https://www.aiom.it/i-numeri-del-cancro-in-italia/
   Google Scholar
• Unger-Saldaña K. Challenges to the early diagnosis and treatment of breast cancer in developing countries. World J Clin Oncol. 2014;5:465–477. doi: 10.5306/wjco.v5.i3.465
   PubMedGoogle Scholar
• Waks AG, Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300. doi: 10.1001/jama.2018.19323
   PubMed Web of Science ®Google Scholar
• Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30(8):1194–1220. doi: 10.1093/annonc/mdz173
   PubMed Web of Science ®Google Scholar
• MAMMELLA AND. 2021;p. 663.
   Google Scholar
• Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987–3998. doi: 10.1200/JCO.20.02514
   PubMed Web of Science ®Google Scholar
• Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: asco clinical practice guideline focused update. J Clin Oncol. 2018. [cited 2021 Dec 8]; Available from. Internet https://ascopubs.org/doi/pdf/10.1200/JCO.18.01160
   Google Scholar
• Salvo EM, Ramirez AO, Cueto J, et al. Risk of recurrence among patients with HR-positive, HER2-negative, early breast cancer receiving adjuvant endocrine therapy: a systematic review and meta-analysis. Breast Edinb Scotl. 2021;57:5–17. doi: 10.1016/j.breast.2021.02.009
   PubMed Web of Science ®Google Scholar
• Di Maio M, Perrone F, Conte P. Real‐world evidence in oncology: Opportunities and limitations. Oncology. 2020;25(5):e746–e752. doi: 10.1634/theoncologist.2019-0647
   Google Scholar
• Guarneri V, Pronzato P, Bertetto O, et al. Use of electronic administrative databases to measure quality indicators of breast cancer care: experience of five regional oncology networks in Italy. JCO Oncol Pract. 2020;16(2):e211–e220. doi: 10.1200/JOP.19.00466
   PubMedGoogle Scholar
• McKay DR, Nguyen P, Wang A, et al. A population-based study of administrative data linkage to measure melanoma surgical and pathology quality. PLoS One. 2022;17(2):e0263713. doi: 10.1371/journal.pone.0263713
   PubMed Web of Science ®Google Scholar
• DECRETO LEGISLATIVO 10 agosto 2018, n. 101 [Internet]. [cited 2023 Jun 29]. Available from. https://www.gazzettaufficiale.it/atto/serie_generale/caricaDettaglioAtto/originario?atto.dataPubblicazioneGazzetta=2018-09-04&atto.codiceRedazionale=18G00129&elenco30giorni=true
   Google Scholar
• Piccinni C, Dondi L, Ronconi G, et al. HR+/HER2- metastatic breast cancer: Epidemiology, prescription patterns, healthcare resource utilisation and costs from a large Italian real-world database. Clin Drug Investig. 2019;39:945–951. doi: 10.1007/s40261-019-00822-4
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi: 10.1016/0021-9681(87)90171-8
   PubMedGoogle Scholar
• Drummond M. Methods for the economic evaluation of health care programmes. Fourth ed. Oxford, (UK) ; New York, NY, USA: Oxford University Press; 2015.
   Google Scholar
• Cortesi PA, Paolicelli D, Capobianco M, et al. The value and sustainability of ocrelizumab in relapsing multiple sclerosis: a cost-effectiveness and budget impact analysis. Farmeconomia Health Econ Ther Pathw. 2019 [[cited 2023 Jun 29]];20. InternetAvailable from: http://journals.seedmedicalpublishers.com/index.php/FE/article/view/1435
   Web of Science ®Google Scholar
• Harbeck N, Rastogi P, Martin M, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol Off J Eur Soc Med Oncol. 2021;32(12):1571–1581. doi: 10.1016/j.annonc.2021.09.015
   PubMed Web of Science ®Google Scholar
• Cognetti F, Masetti R, Fabi A, et al. Pondx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy. NPJ Breast Cancer. 2021;7(1):1–8. doi: 10.1038/s41523-021-00246-4
   PubMed Web of Science ®Google Scholar
• Dengel L, Van Zee KJ, King TA, et al. Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy. Ann Surg Oncol. 2014;21(1):22–27. doi: 10.1245/s10434-013-3200-6
   PubMed Web of Science ®Google Scholar
• Tarantino P, Jin Q, Mittendorf EA, et al. Clinical and pathological features of breast cancer patients eligible for adjuvant abemaciclib. Ann Oncol Off J Eur Soc Med Oncol. 2022;33(8):845–847. doi: 10.1016/j.annonc.2022.04.069
   PubMed Web of Science ®Google Scholar
• Karacin C, Ergun Y, Oksuzoglu OB. Saying goodbye to primary endocrine resistance for advanced breast cancer? Med Oncol Northwood Lond Engl. 2021;38(1):5. doi: 10.1007/s12032-020-01449-8
   PubMed Web of Science ®Google Scholar
• Sheffield KM, Peachey JR, Method M, et al. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer. Future Oncol Lond Engl. 2022;18(21):2667–2682. doi: 10.2217/fon-2022-0310
   PubMed Web of Science ®Google Scholar
• Donker M, van Tienhoven G, Straver ME, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310. doi: 10.1016/S1470-2045(14)70460-7
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (alliance) randomized clinical trial. JAMA. 2017;318(10):918–926. doi: 10.1001/jama.2017.11470
   PubMed Web of Science ®Google Scholar
• Tinterri C, Gentile D, Gatzemeier W, et al. Preservation of axillary lymph nodes compared with complete dissection in T1-2 breast cancer patients Presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial. Ann Surg Oncol. 2022;29:5732–5744. doi: 10.1245/s10434-022-11866-w
   PubMed Web of Science ®Google Scholar